高级检索

富马酸卢帕替芬杂质C制备工艺和结构确证

李琳, 王小明, 孟书舫, 陈琳, 王海燕, 林鹏飞, 陈玲

李琳, 王小明, 孟书舫, 陈琳, 王海燕, 林鹏飞, 陈玲. 富马酸卢帕替芬杂质C制备工艺和结构确证[J]. 中国药科大学学报, 2020, 51(5): 530-537. DOI: 10.11665/j.issn.1000-5048.20200504
引用本文: 李琳, 王小明, 孟书舫, 陈琳, 王海燕, 林鹏飞, 陈玲. 富马酸卢帕替芬杂质C制备工艺和结构确证[J]. 中国药科大学学报, 2020, 51(5): 530-537. DOI: 10.11665/j.issn.1000-5048.20200504
LI Lin, WANG Xiaoming, MENG Shufang, CHEN Lin, WANG Haiyan, LIN Pengfei, CHEN Ling. Preparation process and structure confirmation of impurity C of rupatifen fumarate[J]. Journal of China Pharmaceutical University, 2020, 51(5): 530-537. DOI: 10.11665/j.issn.1000-5048.20200504
Citation: LI Lin, WANG Xiaoming, MENG Shufang, CHEN Lin, WANG Haiyan, LIN Pengfei, CHEN Ling. Preparation process and structure confirmation of impurity C of rupatifen fumarate[J]. Journal of China Pharmaceutical University, 2020, 51(5): 530-537. DOI: 10.11665/j.issn.1000-5048.20200504

富马酸卢帕替芬杂质C制备工艺和结构确证

基金项目: 国家“重大新药创制”科技重大专项资助项目(No.2018ZX09J18108-005);福建省科技重大专项专题资助项目(No.2015YZ0002-2)

Preparation process and structure confirmation of impurity C of rupatifen fumarate

Funds: This study was supported by China National Key Hi-Tech Innovation Project for the R&D of Novel Drugs(No.2018ZX09J18108-005) and Fujian Provincal Science and Technology Major Special Project(No.2015YZ0002-2)
  • 摘要: 以卢帕替芬为原料,经溴代丁二酸亲核取代反应,分离纯化获取高纯度的杂质C化合物,运用IR、UV、MS、1H NMR、13C NMR、DEPT135°、HSQC、HMBC、1H-1HCOSY等技术手段对其结构进行确证。本研究制备的杂质C制备工艺简单、条件温和、易于获得,纯度99.0%,收率25%~30%;并且样品经结构确证符合目标化合物。杂质C的制备和结构确证为新药富马酸卢帕替芬原料及制剂的杂质研究提供了杂质C对照品,为富马酸卢帕替芬质量控制提供了理论依据。
    Abstract: The high-purity impurity C was isolated and purified from a new anti-allergic drug, rupatifen, by nucleophilic substitution reaction with bromobutaric acid, and its structure was confirmed by IR, UV, MS, 1H NMR, 13C NMR, DEPT135°,HSQC, HMBC, and 1H-1HCOSY. The preparation process of impurity C in this study was simple and easy to obtain under mild conditions, with the purity of 99.0% and the yield of 25%-30%;and the sample met the target compound by structural confirmation. The preparation process and structure confirmation provided sufficient impurity C reference substance for impurity research of raw materials and preparations of rupatifen fumarate, which laid a solid foundation for quality research of new drugs.
  • [1] .2016-06-01.
    [2] Fujian Mindong Rejuvenation Pharmaceutical Co.,Ltd.Rupatifen fumarate impurity C, preparation method and detection method thereof:CN,
    201811043105.X[P].2019-01-11.
    [3] Wang C, Zhou MQ, Huang WC. Separation and structural confirmation of 5-methoxybenzo[d]oxazole-2(3H)-thione from key intermediate of omeprazole[J]. Chin J Synth Chem(合成化学), 2018, 26(4):284?287.
    [4] CFDA.The technical guidelines for the preparation and structural confirmation of chemical drug apis[EB/OL].(2007-08-23)[2019-10-20].http://www.cde.org.cn/zdyz.do?method=largePage &id=2067.
    [5] ICH.Impurities in new drug substances(Q3A)[EB/OL].(2006-10-25)[2019-10-21].https://www.ich.org/page/quality-guidelines.
    [6] Compania Uriach Y.Rupatadine salt as an antihistaminic agent:CN,
    201180030958. X[P].2013-03-06[2019-10-20].
    [7] Li LL.Study on the synthesis and impurity of rupatadine fumarate (富马酸卢帕他定的合成及杂质研究)[D].Hangzhou:Zhejiang University,2015.
    [8] Zhao X.synthesis The,structure confirmation and qualitative analysis of rupatadine fumarate (富马酸卢帕他定的化学合成、结构确证和质量分析)[D].Jinan: Shandong University,2008.
    [9] Hu CQ,Zhang X.Current situation and the trend in impurity profiling of chemical drugs[J].Acta Pharm Sin(药学学报),2019,54(12):2214?2231.
计量
  • 文章访问数:  217
  • HTML全文浏览量:  11
  • PDF下载量:  531
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-11-24
  • 修回日期:  2020-08-09
  • 刊出日期:  2020-10-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭